Hyperuricemia is strongly associated with increased cardiometabolic risk, with emerging research supporting its potential pathogenic roles through mechanisms like inflammation and arterial stiffening. While xanthine oxidase inhibitors show benefits in reducing cardiorenal risks, their routine use for asymptomatic hyperuricemia to prevent cardiovascular disease is not yet recommended. Management remains centered on comprehensive lifestyle modifications, and abrupt discontinuation of therapy is advised against due to associated mortality risk.

A clinical trial demonstrates that a novel personalized mRNA-based vaccine triggers a strong immune response against glioblastoma, extending survivability in trial patients.

A comprehensive look at the clinical validation of exagamglogene autotemcel, the first CRISPR-based gene editing therapy approved for sickle cell disease.

How ultra-thin brain-computer interfaces are enabling paralyzed individuals to control robotic limbs and communicate with microscopic latency.